Antibody Targeted Amanitin Conjugates (ATAC): A New Payload Provides New Options for Cancer Therapy

Time: 3:45 pm
day: day 1- pm


  • Discussing a new payload with a new mode of action providing new options to fight cancer
  • Understanding how the ATAC platform optimized the ADC technology for that payload
  • Reviewing HDP-101 targeting BCMA; the first ATAC which cleared IND and is now in dose escalation in myeloma patients